QuidelOrtho (QDEL) Stock Price, News & Analysis

Company Overview

QuidelOrtho Corporation (NASDAQ:QDEL) is a leading developer, manufacturer and marketer of in vitro diagnostic healthcare solutions headquartered in San Diego, California. Through its integrated Quidel and Ortho Clinical Diagnostics business units, the company provides clinicians, laboratories and healthcare providers with rapid diagnostic, molecular testing and blood screening products designed to support patient care and public health initiatives.

The Quidel business unit specializes in immunoassays and molecular diagnostics, offering a broad portfolio of rapid antigen, antibody and molecular tests for infectious diseases, including its proprietary Sofia, Solana and Lyra platforms. Quidel’s assays cover respiratory, gastrointestinal, sexually transmitted and women’s health pathogens, empowering on-the-spot and high-complexity laboratories with fast and accurate results. The company’s molecular instruments, such as the Solana and AmpliVue systems, feature simplified workflows and versatile assay menus that address emerging public health threats.

Through Ortho Clinical Diagnostics, QuidelOrtho delivers transfusion medicine and serology solutions, fielding the VITROS immunodiagnostic system for hospital and reference laboratories worldwide. Ortho’s portfolio includes blood typing, antibody screening and confirmatory tests that ensure safe blood transfusions and immunology diagnostics. The combined organization benefits from complementary research and development capabilities, expanding its pipeline of assays and enhancing manufacturing scale.

Tracing its roots to the 1979 founding of Quidel and the more than 70-year heritage of Ortho Clinical Diagnostics, QuidelOrtho serves customers in over 130 countries. Under the leadership of President and Chief Executive Officer Douglas Bryant, the company maintains manufacturing facilities across North America and Europe and operates a global distribution network. QuidelOrtho continues to invest in innovation, aiming to address evolving healthcare challenges and strengthen its role in diagnostic medicine.

Key Stats

• Today's Range: $30.13 to $31.07
• 50-Day Range: $25.85 to $37.42
• 52-Week Range: $23.77 to $49.45
• Volume: 329,076 shs
• Average Volume: 1.14 million shs
• Market Capitalization: $2.08 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.33
• Consensus Rating: Hold

QuidelOrtho Stock Analysis - MarketRank™

QuidelOrtho scored higher than 89% of companies evaluated by MarketBeat, and ranked 113th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

QuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

QuidelOrtho has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 39.57%

Earnings Growth

Earnings for QuidelOrtho are expected to grow by 39.57% in the coming year, from $2.30 to $3.21 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of QuidelOrtho is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of QuidelOrtho is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

QuidelOrtho has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.07% of the float of QuidelOrtho has been sold short.

Short Interest Ratio / Days to Cover

QuidelOrtho has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in QuidelOrtho has recently increased by 4.09%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

QuidelOrtho does not currently pay a dividend.

Dividend Growth

QuidelOrtho does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -2.61

Percentage of Shares Shorted

6.07% of the float of QuidelOrtho has been sold short.

Short Interest Ratio / Days to Cover

QuidelOrtho has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in QuidelOrtho has recently increased by 4.09%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.78

News Sentiment

QuidelOrtho has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for QuidelOrtho this week, compared to 6 articles on an average week.

Search Interest

Only 3 people have searched for QDEL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, QuidelOrtho insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.79% of the stock of QuidelOrtho is held by insiders.

Percentage Held by Institutions

99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

QDEL Stock Analysis - Frequently Asked Questions

How have QDEL shares performed this year?

QuidelOrtho's stock was trading at $44.55 on January 1st, 2025. Since then, QDEL shares have decreased by 31.2% and is now trading at $30.66.

How were QuidelOrtho's earnings last quarter?

QuidelOrtho Corporation (NASDAQ:QDEL) announced its quarterly earnings data on Wednesday, May, 7th. The company reported $0.74 EPS for the quarter, topping analysts' consensus estimates of $0.61 by $0.13. The company's revenue was down 2.6% compared to the same quarter last year.
Read the conference call transcript.

How do I buy shares of QuidelOrtho?

Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of QuidelOrtho own?

Based on aggregate information from My MarketBeat watchlists, some other companies that QuidelOrtho investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Salesforce (CRM) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:QDEL
• CIK: 353569
• Web: www.quidel.com
• Phone: (800) 874-1517
• Fax: 858-453-4338
• Employees: 6,600
• Year Founded: 1979

Price Target and Rating

• Average Price Target for QuidelOrtho: $44.33
• High Price Target: $61.00
• Low Price Target: $25.00
• Potential Upside/Downside: +43.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 13.40
• P/E Growth: N/A
• Net Income: -$2.05 billion
• Net Margins: -12.07%
• Pretax Margin: -12.35%
• Return on Equity: 4.71%
• Return on Assets: 2.21%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 1.20
• Quick Ratio: 0.66

Sales & Book Value

• Annual Sales: $2.78 billion
• Price / Sales: 0.75
• Cash Flow: $37.59 per share
• Price / Cash Flow: 0.82
• Book Value: $44.38 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 67,630,000
• Free Float: 67,092,000
• Market Cap: $2.08 billion
• Optionable: Optionable
• Beta: 0.07